Drugs / XBI-302
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05352269 | Apr → Aug 2022 | acute graft versus host disease | Shenzhen Xbiome Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05001360 | Oct 2021 → Oct 2023 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Fujian Cancer Hospital | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XBI-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05352269 ↗ |
| Route | Oral | “FMT capsules XBI-302 will be administered orally” NCT05001360 ↗ |